Top-Rated Biotech Stocks

Recs

2

It's typically feast or famine when it comes to biotech stocks, but one big winner can more than make up for a bunch of losers. The secret is finding well-run companies delivering high-quality drugs before the market finds them.

Of course, that's easier said than done, and some biotech companies are already beyond their high-growth stage. Nevertheless, in that spirit, we'll use the aggregate intelligence of the 105,000-plus investors participating in Motley Fool CAPS to find biotech stocks that the community likes -- those with four- and five-star ratings. The community's approval could be a sign that further research is in order.

Here are five such stocks:

Company

Market Cap

% CAPS All-Star Bulls

CAPS Rating
(Out of 5)

CAPS Research

Amgen (Nasdaq: AMGN)

$46.8 B

94.3%

****

AMGN

Genentech (NYSE: DNA)

$77.7 B

96.3%

****

DNA

Genzyme (Nasdaq: GENZ)

$17.4 B

95.1%

*****

GENZ

ViroPharma (Nasdaq: VPHM)

$697 M

98.3%

*****

VPHM

Gilead Sciences (Nasdaq: GILD)

$49.0 B

97.6%

*****

GILD

Source: Motley Fool CAPS, as of June 11, 2008.

Come and join us on CAPS to learn more about these and countless other interesting stock ideas. Sign up for free.

Follow along with the Global Gains team as they travel to key business centers in China to uncover the very best investing opportunities! Sign up here to receive their FREE dispatches from the road.

Disclosure is important to us here at The Motley Fool. The stocks mentioned in this article received their CAPS star ratings from participants in The Motley Fool's CAPS service. No individual person selected the stocks in this article, so there is no author to disclose an interest in them. Since this article was automatically generated by identifying the stocks rated by the CAPS community and by buyers in today's market, it is possible that Motley Fool personnel (and even The Motley Fool itself, through our Million Dollar Portfolio), have positions in these stocks. We thought you'd like to know that. You can learn more about The Motley Fool's disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 663351, ~/articles/ArticleHandler.aspx, 7/14/2009 3:26:59 AM

Keep Reading:

“Top-Rated Biotech Stocks”

We will use your email address only to keep you informed about updates to our web site and about other products and services that we think might interest you. The Motley Fool respects your privacy. Please read our Privacy Statement

.

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

What Fools Are Saying

Get involved! »

Most Popular Articles

  1. The New Subprime6 days ago
  2. What the U.S. Needs: A New Tax System?5 days ago
  3. GM: This Stock Is Worthless3 days ago
Jul 13 at 4:01 PM

Market Summary

DJIA 8,331.68 +185.16 +2.27%
S&P 500 901.05 +21.92 +2.49%
NASD 1,793.21 +37.18 +2.12%
Sponsored by:

Related Tickers

Amgen, Inc.

CAPS Rating 4/5 Stars

$58.01

+0.20 (+0.35%)

Outperform1899

Underperform160

Rate This Stock